Pancreatic Cancer

A novel therapeutic approach that combined radiation and immunotherapy demonstrated the ability to eliminate pancreatic tumors and halt metastases.

From pancreatitis complications to the impact of long COVID, FDA updates to gender disparity in pancreatic cancer, Healio has been at the forefront of coverage for pancreatic disorders in 2023. What have you missed this year?

A multitarget stool DNA methylation assay accurately detected and identified the tissue of origin for multiple gastrointestinal cancers, according to study results presented at ASCO Breakthrough.

The FDA announced several regulatory actions the past few weeks.

Intra-arterial administration of gemcitabine conferred a median PFS benefit of 8 months when compared with standard of care for patients with locally advanced pancreatic cancer, according to results of the phase 3 TiGeR-PaC study.

CHICAGO — First-line NALIRIFOX significantly extended in OS and PFS vs. gemcitabine and nab-paclitaxel among patients with treatment-naive metastatic pancreatic ductal adenocarcinoma, according to a study presented at ASCO Annual Meeting.

Adults with diabetes who use SGLT2 inhibitors have lower risks for developing most types of cancer compared with nonusers, though the risk for pancreatic cancer is higher among SGLT2 users, according to data from researchers in Taiwan.

CHICAGO — The odds of having gastric and pancreatic cancers were higher among postmenopausal women on hormone replacement therapy and remained significant after controlling for risk factors, according to data at Digestive Disease Week.

CHICAGO — Neoadjuvant FOLFIRINOX chemotherapy failed to extend OS compared with upfront surgery for patients with resectable pancreatic head cancer, according to study results presented at ASCO Annual Meeting.

First-degree relatives of individuals with pancreatic ductal adenocarcinoma who harbored certain cancer-associated pathogenic germline variants had significantly higher risk for developing several cancer types, study results showed.